Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
quick quid
Popular Articles

Boston University Biomedical Engineer Wins Hartwell Foundation Grant To Create Pediatric Blood Vessel Grafts That Grow With The Child
Boston University Biomedical Engineer Joyce Wong will work to create engineered blood vessels aimed at correcting pediatric heart defects under a major grant from The Hartwell Foundation. Wong is one of just 12 researchers nationwide to win the foundation"s prestigious Individual Biomedical Research Award.
generic viagra online
Causes And Consequences - Caring For Patients With Intellectual Disability
Patients with developmental disabilities such as Down syndrome or cerebral palsy will benefit from a new online learning activity launched today by The Royal Australian College of General Practitioners (RACGP) to assist GPs to navigate the complex area of developmental disability.
News of the day
'Warrior Gene' Linked To Gang Membership, Weapon Use: FSU Study
Boys who carry a particular variation of the gene Monoamine oxidase A (MAOA), sometimes called the "warrior gene," are more likely not only to join gangs but also to be among the most violent members and to use weapons, according to a new study from The Florida State University that is the first to confirm an MAOA link specifically to gangs and guns.
Oncology

Pharming Receives Agreement On Paediatric Investigation Plan For Rhucin(R) From The EMEA Paediatric Committee

Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today announced that the Paediatric Committee (PDCO) of the European Medicines Agency (EMEA) has adopted an opinion agreeing the paediatric investigation plan (PIP) for Rhucin® (recombinant human C1 inhibitor) in the therapeutic area of immunology-rheumatology transplantation. "Agreement of the PIP represents a key milestone in Pharming"s regulatory plans for the September 2009 submission of the Rhucin marketing authorisation application," said Dr. Bruno Giannetti, COO of Pharming. According to the EC Regulation 1901/2006 of 12 December 2006, pharmaceutical companies that submit an application for a marketing authorisation for a medicinal product (MAA) in the EU, have to include an approved PIP as part of the regulatory submission. Pharming Group NV


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009